The Japan Times
์ค๋ ์ฑํฅ
์ฌํ
Moderna and other groups get $60 million to develop Ebola vaccine
Richard Hatchett, head of CEPI, said that it was possible to get Ebola Bundibugyo (BDBV) vaccines ready for trials within a couple of months.
๐ฏ๐ต ์ผ๋ณธ ยท "VACCINE" ยท ์ด 5๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 1,523๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 0๊ฑด(0.0%)ยท์ค๋ฆฝ 1,523๊ฑด(100.0%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
Richard Hatchett, head of CEPI, said that it was possible to get Ebola Bundibugyo (BDBV) vaccines ready for trials within a couple of months.
Tedros said the rare Bundibugyo strain has no approved โ vaccines or treatments, making early palliative care โ including isolation, rehydration and pain management โ critical.
Caused by a strain of the virus for which there is no vaccine or treatment, the latest outbreak has already caused a suspected 220 deaths and 900 cases.
The outbreak is caused by the rare Bundibugyo strain of the virus and has no approved vaccine or antibody treatment.
There are no vaccines or known drugs specifically approved to treat the rare Bundibugyo strain of Ebola in the Democratic Republic of Congo.